# Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

> **NCT06210971** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** liposomal irinotecan
- **DRUG:** Capecitabine
- **RADIATION:** Radiation threapy

## Key facts

- **NCT ID:** NCT06210971
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06210971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06210971, "Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06210971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*